journal

Journal of Clinical Oncology

journal
https://read.qxmd.com/read/31940221/optimum-imaging-strategies-for-advanced-prostate-cancer-asco-guideline
#1
Edouard J Trabulsi, R Bryan Rumble, Hossein Jadvar, Thomas Hope, Martin Pomper, Baris Turkbey, Andrew B Rosenkrantz, Sadhna Verma, Daniel J Margolis, Adam Froemming, Aytekin Oto, Andrei Purysko, Matthew I Milowsky, Heinz-Peter Schlemmer, Matthias Eiber, Michael J Morris, Peter L Choyke, Anwar Padhani, Jorge Oldan, Stefano Fanti, Suneil Jain, Peter A Pinto, Kirk A Keegan, Christopher R Porter, Jonathan A Coleman, Glenn S Bauman, Ashesh B Jani, Jeffrey M Kamradt, Westley Sholes, H Alberto Vargas
PURPOSE: Provide evidence- and expert-based recommendations for optimal use of imaging in advanced prostate cancer. Due to increases in research and utilization of novel imaging for advanced prostate cancer, this guideline is intended to outline techniques available and provide recommendations on appropriate use of imaging for specified patient subgroups. METHODS: An Expert Panel was convened with members from ASCO and the Society of Abdominal Radiology, American College of Radiology, Society of Nuclear Medicine and Molecular Imaging, American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology to conduct a systematic review of the literature and develop an evidence-based guideline on the optimal use of imaging for advanced prostate cancer...
January 15, 2020: Journal of Clinical Oncology
https://read.qxmd.com/read/31928458/pathological-fracture-and-prognosis-of-high-grade-osteosarcoma-of-the-extremities-an-analysis-of-2-847-consecutive-cooperative-osteosarcoma-study-group-coss-patients
#2
Lisa Marie Kelley, Miriam Schlegel, Stefanie Hecker-Nolting, Matthias Kevric, Bernhard Haller, Claudia Rössig, Peter Reichardt, Leo Kager, Thomas Kühne, Georg Gosheger, Reinhard Windhager, Katja Specht, Hans Rechl, Per-Ulf Tunn, Daniel Baumhoer, Thomas Wirth, Mathias Werner, Thekla von Kalle, Michaela Nathrath, Stefan Burdach, Stefan Bielack, Irene von Lüttichau
PURPOSE: The objective of this study was to investigate potential correlations between pathologic fractures (PFs) and prognosis of patients with primary central high-grade osteosarcoma of the extremities. METHODS: We retrospectively analyzed 2,847 patients registered in the Consecutive Cooperative Osteosarcoma Study Group database with primary central high-grade osteosarcoma of the extremities, treated between 1980 and 2010. Intended treatment included pre- and postoperative chemotherapy and surgery...
January 13, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31928404/estrogen-and-progesterone-receptor-testing-in-breast-cancer-asco-cap-guideline-update
#3
Kimberly H Allison, M Elizabeth H Hammond, Mitchell Dowsett, Shannon E McKernin, Lisa A Carey, Patrick L Fitzgibbons, Daniel F Hayes, Sunil R Lakhani, Mariana Chavez-MacGregor, Jane Perlmutter, Charles M Perou, Meredith M Regan, David L Rimm, W Fraser Symmans, Emina E Torlakovic, Leticia Varella, Giuseppe Viale, Tracey F Weisberg, Lisa M McShane, Antonio C Wolff
PURPOSE: To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen (ER) and progesterone receptor (PgR) testing in breast cancer guideline. METHODS: A multidisciplinary international Expert Panel was convened to update the clinical practice guideline recommendations informed by a systematic review of the medical literature. RECOMMENDATIONS: The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benefit from endocrine therapy, and no other assays are recommended for this purpose...
January 13, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31922929/treatment-of-nodular-lymphocyte-hodgkin-lymphoma-the-goldilocks-principle
#4
Nancy L Bartlett
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
January 10, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31922925/cascading-after-peridiagnostic-cancer-genetic-testing-an-alternative-to-population-based-screening
#5
Kenneth Offit, Kaitlyn A Tkachuk, Zsofia K Stadler, Michael F Walsh, Hector Diaz-Zabala, Jeffrey D Levin, Zoe Steinsnyder, Vignesh Ravichandran, Ravi N Sharaf, Melissa K Frey, Steven M Lipkin, Mark E Robson, Jada G Hamilton, Joseph Vijai, Semanti Mukherjee
PURPOSE: Despite advances in DNA sequencing technology and expanded medical guidelines, the vast majority of individuals carrying pathogenic variants of common cancer susceptibility genes have yet to be identified. An alternative to population-wide genetic screening of healthy individuals would exploit the trend for genetic testing at the time of cancer diagnosis to guide therapy and prevention, combined with augmented familial diffusion or "cascade" of genomic risk information...
January 10, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31922920/individualized-asparaginase-dosing-in-childhood-acute-lymphoblastic-leukemia
#6
Robin Q H Kloos, Rob Pieters, Florine M V Jumelet, Hester A de Groot-Kruseman, Cor van den Bos, Inge M van der Sluis
PURPOSE: In the DCOG ALL-11 protocol, polyethylene glycol-conjugated Escherichia coli asparaginase (PEGasparaginase) and Erwinia asparaginase treatment of pediatric acute lymphoblastic leukemia are individualized with therapeutic drug monitoring (TDM). The efficacy of TDM and its effect on asparaginase-associated toxicity are reported. PATIENTS AND METHODS: After induction with 3 fixed intravenous doses of 1,500 IU/m2 PEGasparaginase, medium-risk patients (n = 243) received 14 individualized doses that targeted trough levels of 100-250 IU/L, standard-risk patients (n = 108) received 1 individualized dose, and high-risk patients (n = 18) received 2-5 fixed administrations (1,500 IU/m2 )...
January 10, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31922918/prospective-feasibility-trial-of-a-novel-strategy-of-facilitated-cascade-genetic-testing-using-telephone-counseling
#7
Melissa K Frey, Ryan M Kahn, Eloise Chapman-Davis, Francesca Tubito, Maira Pires, Paul Christos, Samantha Anderson, Semanti Mukherjee, Bailey Jordan, Stephanie V Blank, Thomas A Caputo, Ravi N Sharaf, Kenneth Offit, Kevin Holcomb, Steven Lipkin
PATIENTS AND METHODS: Probands with newly diagnosed cancer-associated pathogenic variants were offered facilitated cascade testing whereby the genetics team identified and contacted ARRs by telephone to disclose the familial pathogenic variant and offer telephone counseling and mailed saliva testing. Results and guideline-based recommendations were reviewed by telephone and shared with the primary care physician. RESULTS: Thirty probands were enrolled, and 114 ARRs were identified...
January 10, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31895616/reply-to-n-hanna-et-al-and-l-xie-et-al
#8
Suresh S Ramalingam, Suzanne E Dahlberg
No abstract text is available yet for this article.
January 2, 2020: Journal of Clinical Oncology
https://read.qxmd.com/read/31895615/reply-to-k-p-weinfurt-et-al
#9
Nnenaya Q Agochukwu, Daniela Wittmann, Nicholas R Boileau, Rodney L Dunn, James Montie, Tae Kim, David C Miller, James Peabody, Noelle E Carlozzi
No abstract text is available yet for this article.
January 2, 2020: Journal of Clinical Oncology
https://read.qxmd.com/read/31895614/maintenance-therapy-for-advanced-nonsquamous-non-small-cell-lung-cancer-more-questions-than-answers
#10
LETTER
Li Xie, Xingwen Fan, Biyun Qian
No abstract text is available yet for this article.
January 2, 2020: Journal of Clinical Oncology
https://read.qxmd.com/read/31895613/assessing-patient-reported-outcomes-a-negotiated-process
#11
LETTER
Kevin P Weinfurt, Kathryn E Flynn
No abstract text is available yet for this article.
January 2, 2020: Journal of Clinical Oncology
https://read.qxmd.com/read/31895612/the-case-for-maintenance-pemetrexed-plus-bevacizumab
#12
LETTER
Nasser Hanna, Shadia Jalal
No abstract text is available yet for this article.
January 2, 2020: Journal of Clinical Oncology
https://read.qxmd.com/read/31895611/anti-b-cell-maturation-antigen-bite-molecule-amg-420-induces-responses-in-multiple-myeloma
#13
Max S Topp, Johannes Duell, Gerhard Zugmaier, Michel Attal, Philippe Moreau, Christian Langer, Jan Krönke, Thierry Facon, Alexey V Salnikov, Robin Lesley, Karl Beutner, James Kalabus, Erik Rasmussen, Kathrin Riemann, Alex C Minella, Gerd Munzert, Hermann Einsele
PURPOSE: The anti-B-cell maturation antigen BiTE molecule AMG 420 was assessed in patients with relapsed/refractory multiple myeloma. PATIENTS AND METHODS: In this first-in-human study, up to 10 cycles of AMG 420 were given (4-week infusions/6-week cycles). Patients had progression after ≥ 2 lines of prior therapy and no extramedullary disease. Minimal residual disease (MRD) response was defined as < 1 tumor cell/104 bone marrow cells by flow cytometry. RESULTS: Forty-two patients received AMG 420 at 0...
January 2, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31895610/reply-to-k-p-weinfurt-et-al
#14
Andrew J Vickers
No abstract text is available yet for this article.
January 2, 2020: Journal of Clinical Oncology
https://read.qxmd.com/read/31895609/reply-to-t-tanaka-et-al-and-f-liang
#15
Vanita Noronha, Vijay M Patil, Amit Joshi, Nandini Menon, Anuradha Chougule, Kumar Prabhash
No abstract text is available yet for this article.
January 2, 2020: Journal of Clinical Oncology
https://read.qxmd.com/read/31895608/patient-reported-functional-outcomes-after-hypofractionated-or-conventionally-fractionated-radiation-for-prostate-cancer-a-national-cohort-study-in-england
#16
Julie Nossiter, Arunan Sujenthiran, Thomas E Cowling, Matthew G Parry, Susan C Charman, Paul Cathcart, Noel W Clarke, Heather Payne, Jan van der Meulen, Ajay Aggarwal
PURPOSE: The aim of the current study was to determine patient-reported functional outcomes in men with prostate cancer (PCa) undergoing moderately hypofractionated (H-RT) or conventionally fractionated radiation therapy (C-RT) in a national cohort study. PATIENDS AND METHODS: All men diagnosed with PCa between April 2014 and September 2016 in the English National Health Service undergoing C-RT or H-RT were identified in the National Prostate Cancer Audit and mailed a questionnaire at least 18 months after diagnosis...
January 2, 2020: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://read.qxmd.com/read/31895607/statistical-methods-in-precision-oncology
#17
EDITORIAL
Ying Lu, J Jack Lee, James M Ford
No abstract text is available yet for this article.
January 2, 2020: Journal of Clinical Oncology
https://read.qxmd.com/read/31895606/contradiction-between-stated-statistical-analysis-method-and-displayed-survival-curves
#18
LETTER
Fei Liang
No abstract text is available yet for this article.
January 2, 2020: Journal of Clinical Oncology
https://read.qxmd.com/read/31895605/is-gefitinib-combined-with-platinum-doublet-chemotherapy-a-counterpart-to-osimertinib-monotherapy-in-advanced-egfr-mutated-non-small-cell-lung-cancer-in-the-first-line-setting
#19
LETTER
Tomohiro Tanaka, Hiroto Ishiki, Emi Kubo, Sayuri Yokota, Masaki Shimizu, Daisuke Kiuchi, Eriko Satomi
No abstract text is available yet for this article.
January 2, 2020: Journal of Clinical Oncology
https://read.qxmd.com/read/31880969/pharmacogenomics-and-endocrine-therapy-in-breast-cancer
#20
EDITORIAL
Daniel F Hayes, James M Rae
No abstract text is available yet for this article.
December 27, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
journal
journal
20146
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"